Literature DB >> 23739233

Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease.

Sean J Barbour1, Daniel C Cattran, S Joseph Kim, Adeera Levin, Ron Wald, Michelle A Hladunewich, Heather N Reich.   

Abstract

IgA nephropathy (IgAN) accounts for a far higher proportion of end-stage renal disease (ESRD) in Asia compared with North America. It is not known whether this is entirely because of differences in disease prevalence or a higher risk of disease progression. The lack of a racially diverse population cohort followed longitudinally has previously precluded the ability to address this question. To determine whether Asians in North America with IgAN are at higher risk for ESRD, we analyzed a cohort of 202 patients of self-reported Pacific Asian origin and 467 of other origin from the Toronto GN Registry followed up for a median of 46.4 months. The primary outcome of ESRD (dialysis, transplantation, or eGFR below 15) was analyzed using Cox regression analysis. Baseline eGFR was 59.6 ml/min/1.73 m(2), and median proteinuria was 1.8 g/day. ESRD occurred in 213 patients. By univariable analysis, the risk of ESRD was similar between the two groups (hazard ratio 0.98, 95% CI 0.73, 1.31); however, after adjusting for age, gender, eGFR, medication use, blood pressure, and proteinuria, the risk of ESRD was significantly higher in Pacific Asian individuals (hazard ratio 1.56, 95% CI 1.10, 2.22). This was supported by a significant 1.62 ml/min/1.73 m(2)/year faster rate of eGFR decline (95% CI -3.19, -0.5) and an increased risk of a reduction in eGFR by half (hazard ratio 1.81, 95% CI 1.25, 2.62). Thus, in a large multiracial cohort of patients with IgAN, individuals of Pacific Asian origin have a higher risk of progression to ESRD.

Entities:  

Mesh:

Year:  2013        PMID: 23739233     DOI: 10.1038/ki.2013.210

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  41 in total

Review 1.  IgA Nephropathy.

Authors:  Jennifer C Rodrigues; Mark Haas; Heather N Reich
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 8.237

2.  A case of IgA nephropathy with deep venous thrombosis in the mesentery and lower extremities.

Authors:  Hong Tang; Lei Zhang; Wei Zhao; Rongquan Chen; Min Xie
Journal:  Quant Imaging Med Surg       Date:  2018-12

3.  Remission of Hematuria Improves Renal Survival in IgA Nephropathy.

Authors:  Angel M Sevillano; Eduardo Gutiérrez; Claudia Yuste; Teresa Cavero; Evangelina Mérida; Paola Rodríguez; Ana García; Enrique Morales; Cristina Fernández; Miguel Angel Martínez; Juan Antonio Moreno; Manuel Praga
Journal:  J Am Soc Nephrol       Date:  2017-06-07       Impact factor: 10.121

4.  Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.

Authors:  Sean J Barbour; Rosanna Coppo; Hong Zhang; Zhi-Hong Liu; Yusuke Suzuki; Keiichi Matsuzaki; Ritsuko Katafuchi; Lee Er; Gabriela Espino-Hernandez; S Joseph Kim; Heather N Reich; John Feehally; Daniel C Cattran
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

5.  Mesangial C3 deposition and serum C3 levels predict renal outcome in IgA nephropathy.

Authors:  Dan Wu; Xueqian Li; Xingfeng Yao; Nan Zhang; Lei Lei; Hejia Zhang; Mengmeng Tang; Jie Ni; Chen Ling; Zhi Chen; Xiangmei Chen; Xiaorong Liu
Journal:  Clin Exp Nephrol       Date:  2021-02-23       Impact factor: 2.801

6.  Ethnic Differences in Incidence and Outcomes of Childhood Nephrotic Syndrome.

Authors:  Tonny H M Banh; Neesha Hussain-Shamsy; Viral Patel; Jovanka Vasilevska-Ristovska; Karlota Borges; Cathryn Sibbald; Deborah Lipszyc; Josefina Brooke; Denis Geary; Valerie Langlois; Michele Reddon; Rachel Pearl; Leo Levin; Monica Piekut; Christoph P B Licht; Seetha Radhakrishnan; Kimberly Aitken-Menezes; Elizabeth Harvey; Diane Hebert; Tino D Piscione; Rulan S Parekh
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-21       Impact factor: 8.237

7.  Initial serum creatinine concentration affects clinical outcomes in patients with IgA nephropathy treated with mycophenolate mofetil combined with low-dose prednisone.

Authors:  Haiying Song; Haofei Hu; Fei Tang; Changchun Cao; Qijun Wan; Yongcheng He
Journal:  Exp Ther Med       Date:  2020-03-05       Impact factor: 2.447

8.  IgA Nephropathy Susceptibility Loci and Disease Progression.

Authors:  Manman Shi; Yan Ouyang; Mingxin Yang; Meng Yang; Xiaoyan Zhang; Wei Huang; Weiming Wang; Zhaohui Wang; Wen Zhang; Xiaonong Chen; Xiaoxia Pan; Hong Ren; Nan Chen; Jingyuan Xie
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-24       Impact factor: 8.237

9.  Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease.

Authors:  Xiao-Wei Li; Shao-Shan Liang; Wei-Bo Le; Shui-Qin Cheng; Cai-Hong Zeng; Jin-Quan Wang; Zhi-Hong Liu
Journal:  J Nephrol       Date:  2015-11-04       Impact factor: 3.902

10.  Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

Authors:  Jicheng Lv; Hong Zhang; Muh Geot Wong; Meg J Jardine; Michelle Hladunewich; Vivek Jha; Helen Monaghan; Minghui Zhao; Sean Barbour; Heather Reich; Daniel Cattran; Richard Glassock; Adeera Levin; David Wheeler; Mark Woodward; Laurent Billot; Tak Mao Chan; Zhi-Hong Liu; David W Johnson; Alan Cass; John Feehally; Jürgen Floege; Giuseppe Remuzzi; Yangfeng Wu; Rajiv Agarwal; Hai-Yan Wang; Vlado Perkovic
Journal:  JAMA       Date:  2017-08-01       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.